Figure S17 from Genome-Wide CRISPR Screening Reveals That mTOR Inhibition Initiates Ferritinophagy and Ferroptosis in Head and Neck Cancer

Keiichi Koshizuka; Xingyu Wu; Kuniaki Sato; Pham Thuy Tien Vo; Gosia M. Murawska; Tomohiko Ishikawa; Zhiyong Wang; Alfredo A. Molinolo; Edward A. Dennis; Cherie‐Ann O. Nathan; Prashant Mali; J. Silvio Gutkind

doi:10.1158/0008-5472.29919032

August 15, 2025Open Access

Figure S17 from Genome-Wide CRISPR Screening Reveals That mTOR Inhibition Initiates Ferritinophagy and Ferroptosis in Head and Neck Cancer

View Full Paper

Ask AI

Bookmark

Share

Key Points

Tumor control is significantly enhanced when combining mTOR inhibitors and auranofin in vivo.
The study reveals that mTOR inhibition triggers ferritinophagy and ferroptosis in head and neck cancer models.
This observational analysis incorporated various cancer models to see the effects of mTOR inhibition.
These findings highlight the potential for new therapeutic strategies targeting mTOR in cancer treatment.

Implication

Observational analysis shows enhanced tumor control and ferroptosis in head and neck cancer, indicating potential therapeutic benefits of mTOR inhibitors and auranofin.

Abstract

Increased tumor control and enhanced ferroptosis by the combination of mTORi and auranofin in vivo. (Related to Figure 7)

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Koshizuka et al. (2025) studied this question.

synapsesocial.com/papers/68af56faad7bf08b1eadd1ea https://doi.org/10.1158/0008-5472.29919032

View Full Paper

Ask AI

Bookmark

Share

Figure S17 from Genome-Wide CRISPR Screening Reveals That mTOR Inhibition Initiates Ferritinophagy and Ferroptosis in Head and Neck Cancer

Key Points

Implication

Abstract

Discussion

Cite This Study

Figure S17 from Genome-Wide CRISPR Screening Reveals That mTOR Inhibition Initiates Ferritinophagy and Ferroptosis in Head and Neck Cancer

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading